OCU400 Clinical Trial Enrollment Completed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy OCGN?
Source: Newsfilter
- Trial Enrollment Completed: The liMeliGhT clinical trial for OCU400 has successfully enrolled 140 patients, reflecting strong interest from investigators and patients, marking a significant step towards potentially launching the first gene therapy candidate for RP in 2027.
- Data Release Expectations: Topline data expected in Q1 2027 will support the Biologics License Application (BLA) for OCU400, providing a new treatment option for early to late-stage retinitis pigmentosa patients and addressing a significant market gap.
- Long-term Efficacy Validation: OCU400 demonstrated approximately 2-line visual improvement over three years in Phase 1/2 trials, with 88% of treated subjects showing vision preservation or improvement, reinforcing its safety and tolerability profile and potentially shifting the treatment paradigm for RP.
- Gene-Agnostic Mechanism: This trial is the only broad gene-agnostic RP study, aiming to target multiple genetic mutations with a single therapeutic approach, showcasing OCU400's potential to offer effective treatment options for the 98% of RP patients who are not candidates for existing gene therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCGN
Wall Street analysts forecast OCGN stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.660
Low
7.00
Averages
7.67
High
8.00
Current: 1.660
Low
7.00
Averages
7.67
High
8.00
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ocugen Reports Q4 and Full-Year 2025 Financial Results
- Financial Overview: Ocugen reported a net loss of $0.06 per share for Q4 2025, widening from a $0.05 loss in Q4 2024, indicating ongoing financial challenges despite significant business progress.
- Cash Position: As of year-end 2025, Ocugen had $18.9 million in cash and restricted cash, with proceeds from January 2026 financing expected to fund operations into Q4 2026, potentially extending to Q2 2027 if warrants are exercised, ensuring liquidity for critical regulatory milestones.
- Clinical Progress: OCU400, the lead gene therapy candidate for retinitis pigmentosa, has completed enrollment in the Phase 3 liMeliGhT trial, with topline data expected in Q1 2027, advancing its path toward potential approval.
- New Product Development: Ocugen's inhaled COVID-19 vaccine candidate, OCU500, is expected to enter Phase 1 clinical trials in Q2 2026, reflecting the company's ongoing commitment to pandemic response, while the establishment of OrthoCellix aims to independently finance and develop the NeoCart cartilage repair platform.
See More
Ocugen Q4 2025 Earnings Call Insights Highlight Growth and Strategic Developments
- Clinical Trial Progress: Ocugen has completed enrollment for the OCU400 Phase III liMeliGhT trial, which is the only broad RP gene-agnostic trial, and is on track to begin rolling BLA submissions in Q3 2026, marking significant advancement in the gene therapy sector.
- Regional Licensing Agreement: The company signed its first regional licensing agreement for OCU400 in Korea, which includes upfront fees and milestone payments, expected to generate substantial revenue streams and further drive Ocugen's business development strategy.
- Financial Performance: In Q4 2025, research and development expenses totaled $10.7 million, with a net loss of $0.06 per share; despite the increase in losses, the company bolstered its cash flow through a $22.5 million direct stock offering, ensuring operational runway into Q4 2026.
- Leadership Team Expansion: Ocugen appointed several new executives, including Abhi Gupta as EVP of Commercial and Business Development and Rita Johnson-Greene as CFO, enhancing the company's leadership capabilities and laying a solid foundation for future commercialization and market competitiveness.
See More
Ocugen Reports Q4 2025 Financial Results
- Financial Performance: Ocugen reported a GAAP EPS of -$0.06 for Q4 2025, aligning with expectations and indicating a degree of financial stability despite ongoing losses.
- Cash Position: As of December 31, 2025, Ocugen's cash and restricted cash totaled $18.9 million, a significant decline from $58.8 million on December 31, 2024, highlighting pressures in cash management.
- Funding Outlook: The company anticipates that the $22.5 million financing in January 2026 will enable it to fund operations into Q4 2026, reflecting a positive outlook on future cash flow despite current funding challenges.
- Cash Runway Extension: If the Janus Henderson warrants are fully exercised this year, it is expected that the cash runway will extend into Q2 2027, providing greater assurance for the company's long-term operational viability.
See More
OCUGEN REPORTS Q4 NET LOSS OF USD 17.706 MILLION
- Financial Performance: OCUGEN reported a net income of USD 17.706 million for Q4.
- Quarterly Results: The financial results indicate a significant performance in the fourth quarter.
See More
OCUGEN REPORTS Q4 OPERATING EXPENSES OF $16.802 MILLION
- Operating Expenses: The operating expenses for Q4 are reported to be USD 16.802 million.
- Financial Overview: The financial data indicates a significant expenditure in the operational sector for the specified quarter.
See More
Ocugen Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Ocugen is set to release its Q4 earnings on March 4 before market open, with a consensus EPS estimate of -$0.06, reflecting a 20% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $0.86 million, representing a 13.2% year-over-year increase, indicating a gradual recovery in the company's market position that could positively influence future investment decisions.
- Performance Track Record: Over the past year, Ocugen has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating a level of stability and reliability in its financial performance that may attract investor interest.
- Stock Offering: Ocugen successfully priced a $22.5 million common stock offering at $1.50 per share, providing essential funding to support its ongoing R&D and market expansion initiatives.
See More
Ocugen Reports Q4 and Full-Year 2025 Financial Results
- Financial Overview: Ocugen reported a net loss of $0.06 per share for Q4 2025, widening from a $0.05 loss in Q4 2024, indicating ongoing financial challenges despite significant business progress.
- Cash Position: As of year-end 2025, Ocugen had $18.9 million in cash and restricted cash, with proceeds from January 2026 financing expected to fund operations into Q4 2026, potentially extending to Q2 2027 if warrants are exercised, ensuring liquidity for critical regulatory milestones.
- Clinical Progress: OCU400, the lead gene therapy candidate for retinitis pigmentosa, has completed enrollment in the Phase 3 liMeliGhT trial, with topline data expected in Q1 2027, advancing its path toward potential approval.
- New Product Development: Ocugen's inhaled COVID-19 vaccine candidate, OCU500, is expected to enter Phase 1 clinical trials in Q2 2026, reflecting the company's ongoing commitment to pandemic response, while the establishment of OrthoCellix aims to independently finance and develop the NeoCart cartilage repair platform.
See More
Ocugen Q4 2025 Earnings Call Insights Highlight Growth and Strategic Developments
- Clinical Trial Progress: Ocugen has completed enrollment for the OCU400 Phase III liMeliGhT trial, which is the only broad RP gene-agnostic trial, and is on track to begin rolling BLA submissions in Q3 2026, marking significant advancement in the gene therapy sector.
- Regional Licensing Agreement: The company signed its first regional licensing agreement for OCU400 in Korea, which includes upfront fees and milestone payments, expected to generate substantial revenue streams and further drive Ocugen's business development strategy.
- Financial Performance: In Q4 2025, research and development expenses totaled $10.7 million, with a net loss of $0.06 per share; despite the increase in losses, the company bolstered its cash flow through a $22.5 million direct stock offering, ensuring operational runway into Q4 2026.
- Leadership Team Expansion: Ocugen appointed several new executives, including Abhi Gupta as EVP of Commercial and Business Development and Rita Johnson-Greene as CFO, enhancing the company's leadership capabilities and laying a solid foundation for future commercialization and market competitiveness.
See More
Ocugen Reports Q4 2025 Financial Results
- Financial Performance: Ocugen reported a GAAP EPS of -$0.06 for Q4 2025, aligning with expectations and indicating a degree of financial stability despite ongoing losses.
- Cash Position: As of December 31, 2025, Ocugen's cash and restricted cash totaled $18.9 million, a significant decline from $58.8 million on December 31, 2024, highlighting pressures in cash management.
- Funding Outlook: The company anticipates that the $22.5 million financing in January 2026 will enable it to fund operations into Q4 2026, reflecting a positive outlook on future cash flow despite current funding challenges.
- Cash Runway Extension: If the Janus Henderson warrants are fully exercised this year, it is expected that the cash runway will extend into Q2 2027, providing greater assurance for the company's long-term operational viability.
See More
OCUGEN REPORTS Q4 NET LOSS OF USD 17.706 MILLION
- Financial Performance: OCUGEN reported a net income of USD 17.706 million for Q4.
- Quarterly Results: The financial results indicate a significant performance in the fourth quarter.
See More
OCUGEN REPORTS Q4 OPERATING EXPENSES OF $16.802 MILLION
- Operating Expenses: The operating expenses for Q4 are reported to be USD 16.802 million.
- Financial Overview: The financial data indicates a significant expenditure in the operational sector for the specified quarter.
See More
Ocugen Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Ocugen is set to release its Q4 earnings on March 4 before market open, with a consensus EPS estimate of -$0.06, reflecting a 20% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $0.86 million, representing a 13.2% year-over-year increase, indicating a gradual recovery in the company's market position that could positively influence future investment decisions.
- Performance Track Record: Over the past year, Ocugen has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating a level of stability and reliability in its financial performance that may attract investor interest.
- Stock Offering: Ocugen successfully priced a $22.5 million common stock offering at $1.50 per share, providing essential funding to support its ongoing R&D and market expansion initiatives.
See More
